

CENTRAL DIABETES INSIPIDUS AFTER ABDOMINAL SURGERY: A CASE REPORT

Aarti Maharaj¹, Kundan Jana¹, Kalyana Janga¹, Sheldon Greenberg¹, and Elie Fein¹

¹Maimonides Medical Center

February 22, 2024

Abstract

Post-operative polyuria due to Diabetes Insipidus is a commonly reported complication of pituitary surgery. However, central DI post abdominal surgery is rare and may be related to pre-existing DI or prolonged surgery with intraoperative blood loss. A thorough workup needs to be done to exclude central DI in such patients.

INTRODUCTION

Post-operative polyuria is a well-documented complication of prolonged surgeries. The increased sympathetic drive during surgery leads to stimulation of vasopressin and aldosterone. This stimulation, coupled with the large amounts of intravenous fluid patients receive during surgery, promotes fluid retention¹. Decrease in the levels of vasopressin and aldosterone after surgery causes release of retained fluids leading to polyuria. However, polyuria can also be caused by Diabetes Insipidus (DI). While, post-operative Diabetes Insipidus can be transient or permanent depending on the extent of injury to the pituitary gland and is most commonly associated with pituitary surgeries². Very few cases have been reported after abdominal surgeries. Here we report the case of a 48-year-old woman who developed central DI due to prolonged abdominal surgery with significant intraoperative blood loss.

CASE PRESENTATION

A 48-year-old woman presented with a one-year history of irregular heavy vaginal bleeding. She was hemodynamically stable at presentation and physical examination was unremarkable. Bimanual examination revealed the cervix to be thin and dilated to 8cm with a large mass protruding from the external os suspicious for an aborting myoma. Initial laboratory investigations are summarized in table 1. A total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO) was planned and she was optimized with blood transfusions, IV fluids and tranexamic acid.

Her surgical course was complicated by left ureteral injury requiring left intravesical ureteral reimplant and left ureteral stent placement by urology. Serum osmolality increased from 287 mosm/kg on admission to 322 mosm/kg. Urine electrolytes were performed at this time which showed urine osmolality of 93 mOsm/kg, urine sodium of 23 mmol/L, urine chloride 30 mmol/L, urine potassium of 9.0 mmol/L and urine creatinine of 23.5 mg/dl. Twenty-four urinary output on post-operative Day 1 was 7.1L and 11.9L on postoperative Day 2. She was extubated on postoperative Day 2. Renal ultrasonography (Day 4 post-operation) showed adequate placement of the left ureteral stent with left hydronephrosis.

Given the timeline of events, it was unclear if the polyuria was secondary to ureteral injury and post-obstructive diuresis versus diabetes insipidus. She was treated with intravenous desmopressin with a marked reduction in urine output to 4.2L in 24 hours and increased urine osmolality (315m Osm/kg). MRI brain was performed which showed absence of the posterior pituitary bright spot consistent with posterior pituitary

dysfunction suggestive of central diabetes insipidus (DI) (See Figure 1). Further investigation revealed normal ACTH, cortisol, TSH and IgG levels. She was encouraged to drink to meet the demand of her thirst level and was treated with desmopressin when her urine output was more than or equal to 300ml/hr for 3 consecutive hours and serum sodium was more than 145 mmol/L. She was discharged on Desmopressin 0.1 mg daily.

DISCUSSION

Diabetes insipidus (DI) is a form of polyuria–polydipsia syndrome and is characterized by excessive hypotonic polyuria (>50 mL/kg body weight/24 h) and polydipsia (>3 L/day)³. It is characterized by the body's inability to retain free water and typically presents with polyuria, insatiable thirst and symptoms associated with dehydration. It is a rare disease with a prevalence of ~ 1 in 25,000 individuals or about 0.004% of the global population with no gender predilection^{4, 5}.

DI may occur due to four fundamentally different defects in the physiological control of water balance including impaired antidiuretic hormone (ADH) secretion (central DI), impaired renal response to ADH (nephrogenic DI), excessive fluid intake (primary polydipsia), or increased metabolism of the ADH (gestational diabetes insipidus)³. The diagnostic challenge for the clinician is to confirm the presence of polyuria and distinguish between the various disease processes. Reliable distinction between the different etiologies of DI is imperative since treatment differs substantially. In this case report, we focus on central DI (CDI) which was diagnosed after TAH and BSO complicated by ureteral injury.

CDI is the most common type of DI. It results from inadequate synthesis of ADH by the supraoptic or paraventricular nuclei in the hypothalamus or impaired release of ADH from the posterior pituitary gland³. Acquired factors such as iatrogenic post neurosurgery (20%), hypothalamo-neurohypophyseal axis lesions (20%) and head trauma (16%), account for the majority of cases of CDI⁶. The inherited/familial causes account for 1% of CDI cases. Additionally, a large proportion of the cases of CDI (30-50%) is idiopathic and has been associated with destruction of the hormone secreting cells in the hypothalamic nuclei due to an autoimmune process⁷.

While most of the post-operative DI cases reported have been associated with pituitary/cranial surgery, cases of DI after abdominal surgery are very rare. The diagnosis of an isolated posterior pituitary dysfunction was made after gynecological surgery in one case⁸, whereas one patient was reported to have developed DI after liver transplantation surgery⁹. The cause of DI in the latter case has not been clearly delineated. Other causes reported include cobalt induced DI from hip prosthesis and propofol induced DI^{10, 11}.

Our patient developed central DI, as evidenced by the MRI findings and response to desmopressin, after surgery. The surgery itself was prolonged and had a complicated course with extensive blood loss (more than 2 liters) requiring multiple transfusions. The patient was having heavy irregular menstrual bleeds for more than a year before surgery. Coupled with this, the large amounts of blood loss during surgery could have contributed to posterior pituitary ischemia leading to impaired synthesis and release of ADH.

The presence of intraoperative ureteral injury with urological intervention and following hydronephrosis created suspicion for post-obstructive diuresis being the culprit of the patient's polyuria. Therefore, the key step in identifying DI in this case was the presence of hypotonic urine (urine osmolality of 90 mOsm/kg) which ruled out osmotic diuresis.

The indirect water deprivation test has been documented as the gold standard in literature for diagnosing DI. It involves depriving the patient of fluids and regularly measuring the patient's urinary excretion, urine osmolality, plasma sodium, and plasma osmolality. The fluid deprivation is continued for either seventeen hours maximum, until plasma concentration is greater than or equal to 150 mmol/L, or a loss of 3%-5% of the patient's body weight has occurred¹². After exogenous administration of synthetic ADH, or desmopressin (DDAVP), the patient's urine osmolality is measured to compare to the osmolality before DDAVP administration. At the end of the test, the urine osmolality for healthy individuals should be above 800 mOsm/kg osmolality with no increase in urine osmolality following DDAVP. Both nephrogenic and

central DI will have urine osmolality below 300 mOsm/kg¹³. Although the indirect water deprivation test was not officially done for this patient, after fourteen hours of fasting, she was noted to have urine osmolality of 93 mOsm/kg. The response to DDAVP differentiates nephrogenic and central DI. After DDAVP, urine osmolality will increase >50% for CDI and <50% for NDI. Our patient's urine osmolality increased from 93 mOsm/kg to 315 mOsm/kg after administration of DDAVP pointing to a diagnosis of CDI.

Further workup in patients with CDI includes biochemical evaluation of a morning plasma measurement of pituitary hormones (growth hormone, ACTH, TSH, FSH and LH) and hormones from their target organs. An MRI of the sella and suprasellar regions with gadolinium would identify any anatomical pituitary or hypothalamic disruptions (macroadenomas, empty sella, infiltrative diseases). The normal posterior pituitary demonstrates hyperintensity on T1 images (also known as the 'bright spot'), suggested to be due to phospholipid-rich granules storing AVP and oxytocin¹⁴. As seen in this case, the absence of this bright spot could indicate an absence of posterior pituitary function (See Figure 1).

To avoid the main adverse effect of hyponatremia, the minimum desmopressin dose required to control symptoms should be started. A retrospective review has shown that 27% of central DI patients show mild hyponatremia on routine electrolyte testing and 15% develop more severe hyponatremia, over long-term follow-up¹⁵.

In conclusion, accurate diagnosis of DI and ascertaining the underlying cause poses a challenge in present clinical practice. The appropriate diagnosis is critical to ensure improved quality of life for the patient. The first step in approaching patients with polyuria-polydipsia syndrome is appropriate medical history and examination, baseline laboratory assessment using serum electrolytes and urine osmolality. The indirect water deprivation test, although cumbersome, can provide a diagnosis with increased accuracy. There is also promising potential for the utility of copeptin levels in the future. Most ambulatory patients remain eunatremic due to the compensatory thirst mechanism associated with DI. However, desmopressin remains widely used in the treatment of DI. It is recommended to start with the lowest dose to achieve symptom control to avoid hyponatremia.

AUTHOR CONTRIBUTIONS

AM and KJ reviewed the literature and wrote the manuscript; KCJ, EF and SG conceptualized the idea and were involved in the treatment of the patient; all authors read and approved the final version of the manuscript.

REFERENCES

1. Kristof RA, Rother M, Neuloh G, Klingmuller D. Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study. *J Neurosurg.* Sep 2009;111(3):555-62. doi:10.3171/2008.9.JNS08191
2. Schreckinger M, Szerlip N, Mittal S. Diabetes insipidus following resection of pituitary tumors. *Clin Neurol Neurosurg.* Feb 2013;115(2):121-6. doi:10.1016/j.clineuro.2012.08.009
3. Robertson GL. Diabetes insipidus. *Endocrinol Metab Clin North Am.* Sep 1995;24(3):549-72.
4. Kalra S, Zargar AH, Jain SM, et al. Diabetes insipidus: The other diabetes. *Indian J Endocrinol Metab.* Jan-Feb 2016;20(1):9-21. doi:10.4103/2230-8210.172273
5. Christ-Crain M, Bichet DG, Fenske WK, et al. Diabetes insipidus. *Nat Rev Dis Primers.* Aug 8 2019;5(1):54. doi:10.1038/s41572-019-0103-2
6. Adams NC, Farrell TP, O'Shea A, et al. Neuroimaging of central diabetes insipidus-when, how and findings. *Neuroradiology.* Oct 2018;60(10):995-1012. doi:10.1007/s00234-018-2072-7
7. Maghnie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. *N Engl J Med.* Oct 5 2000;343(14):998-1007. doi:10.1056/NEJM200010053431403

8. Adali E, Kucukaydin Z, Adali F, Yildizhan R. Isolated impairment of posterior pituitary function secondary to severe postpartum haemorrhage due to uterine rupture. *Gynecol Endocrinol*. Aug 2011;27(8):541-2. doi:10.3109/09513590.2010.501877
9. Pal A, Malik A, Goyal N. Postoperative diabetes insipidus in liver transplantation - A case report. *Indian J Anaesth*. Jun 2019;63(6):497-498. doi:10.4103/ija.IJA_895_18
10. Shaheen A, Dobish M, Gleason V, Setren A, Stem J, Kohl BA. A 61-year-old woman develops polyuria after hip revision. *J Surg Case Rep*. May 11 2016;2016(5)doi:10.1093/jscr/rjw079
11. Soo J, Gray J, Manecke G. Propofol and diabetes insipidus. *J Clin Anesth*. Dec 2014;26(8):679-83. doi:10.1016/j.jclineane.2014.02.012
12. Refardt J, Winzeler B, Christ-Crain M. Diabetes Insipidus: An Update. *Endocrinol Metab Clin North Am*. Sep 2020;49(3):517-531. doi:10.1016/j.ecl.2020.05.012
13. Refardt J. Diagnosis and differential diagnosis of diabetes insipidus: Update. *Best Pract Res Clin Endocrinol Metab*. Sep 2020;34(5):101398. doi:10.1016/j.beem.2020.101398
14. Brooks BS, el Gammal T, Allison JD, Hoffman WH. Frequency and variation of the posterior pituitary bright signal on MR images. *AJR Am J Roentgenol*. Nov 1989;153(5):1033-8. doi:10.2214/ajr.153.5.1033
15. Behan LA, Sherlock M, Moyles P, et al. Abnormal plasma sodium concentrations in patients treated with desmopressin for cranial diabetes insipidus: results of a long-term retrospective study. *Eur J Endocrinol*. Mar 2015;172(3):243-50. doi:10.1530/EJE-14-0719

Figure Legends:

Figure 1: Sagittal view of the MRI brain highlighting loss of the pituitary bright spot (orange arrow)

Table Legends:

Table 1: Laboratory values of the patient during course of hospitalisation

Abbreviations used: BUN: Blood Urea Nitrogen; POD: Post-Operative Day; Units in parentheses

Table 1: Laboratory values of the patient during hospitalisation

		POD #1	POD #3	POD #5	At discharge
Urinalysis	Urine Osmolality (mosm/kg)	93	218	264	315
	Urine Sodium (mmol/l)	23	72	117	53
	Urine Potassium (mmol/l)	9	16	15	16
	Urine Chloride (mmol/l)	30	87	99	98
	Urine Creatinine (mg/dl)	23.5	27.2	12.9	67.3
	Urine specific gravity	1.005			
Metabolic Profile	Glucose (mg/dl)	88	123	99	96
	BUN (mg/dl)	2.86	7.62	5.62	3.56
	Creatinine (mg/dl)	0.7	1	0.5	0.5
	Serum Sodium (mmol/l)	144	156	140	139
	Serum Potassium (mmol/l)	3.4	3.6	3.6	4
	Serum Chloride (mmol/l)	112	122	113	109
	Serum Albumin (g/dl)	3.8			
	Serum Osmolality (mosm/kg)	291			

BUN: Blood Urea Nitrogen; POD: Post-Operative Day; Units in parentheses

